Full-Time

Senior Manager

Corporate Regulatory Affairs

Posted on 8/30/2024

Corcept Therapeutics

Corcept Therapeutics

501-1,000 employees

Develops cortisol modulators for medical conditions

Compensation Overview

$180k - $210k/yr

Senior

Menlo Park, CA, USA

Onsite in Menlo Park, CA, typically 3 days per week.

Category
Risk & Compliance
Legal & Compliance
Requirements
  • 5 + years of experience in Regulatory Affairs in the biotechnology or pharmaceutical industries
  • Bachelor’s or advanced degree preferred (M.S., Pharm.D., M.D., Ph.D.) in a scientific discipline
  • Strong analytical and problem-solving skills
  • Strong written and verbal communication skills, including the ability to interact effectively and to influence
  • Strong attention to detail
  • Customer focused and adaptable, with the ability to balance and manage multiple projects from multiple stakeholders to time and quality expectations
  • High functioning as both a team player and individual contributor
Responsibilities
  • Manages most aspects of company regulatory interface with domestic and international health authorities
  • Manages the development and deployment of the regulatory program that ensures aggressive product approval
  • Manages and may generate regulatory submission documents for new products or changes to existing health authorities' filings, including domestic and international submissions and registration
  • Manages the submissions of clinical study submissions
  • Determines governmental regulations affecting company processes and assures the processes are complete and accurate to ensure company compliance
  • Partners with various teams throughout organization (Clinical Operations, R&D, Quality, etc.) on projects
  • Works with clinical team to assure appropriate organization and data are used for regulatory submissions and clinical presentations
  • Provides guidance with localization and labeling requirements
  • Manages regulatory reporting

Corcept Therapeutics focuses on developing treatments that regulate cortisol levels in the body, which is important for managing stress, metabolism, and immune functions. Their main product, Korlym, is the first FDA-approved treatment for Cushing's syndrome, a condition caused by excessive cortisol. Corcept has created over 1,000 cortisol modulators through extensive research and development, aiming to expand their treatment options for patients with cortisol-related disorders. Unlike many competitors, Corcept not only sells its approved drug but also invests in patient and medical education to enhance understanding and care for these conditions. The company's goal is to improve the lives of patients suffering from serious medical issues related to cortisol imbalance.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Menlo Park, California

Founded

1998

Simplify Jobs

Simplify's Take

What believers are saying

  • Corcept's stock is the best performing pharma stock in 2025.
  • The MOMENTUM trial could expand Corcept's market reach.
  • Recent investments show growing confidence in Corcept's future prospects.

What critics are saying

  • Securities fraud investigations could lead to legal and financial repercussions.
  • Teva's antitrust lawsuit may result in legal challenges.
  • Potential reputation damage from ongoing legal investigations.

What makes Corcept Therapeutics unique

  • Corcept specializes in cortisol modulation, a niche with few competitors.
  • Korlym is the first FDA-approved treatment for Cushing's syndrome.
  • Corcept has discovered over 1,000 selective cortisol modulators.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

1%

2 year growth

-3%
Access News Wire
Mar 18th, 2025
Shareholders that lost money on Corcept Therapeutics Incorporated(CORT) should contact Levi & Korsinsky about Securities Fraud Investigation - CORT

NEW YORK, NY / ACCESS Newswire / March 18, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Corcept Therapeutics Incorporated ("Corcept Therapeutics Incorporated") (NASDAQ:CORT) concerning possible violations of federal securities laws.

Stock Titan
Mar 10th, 2025
Corcept Therapeutics Initiates MOMENTUM Trial to Determine Prevalence of Hypercortisolism in Patients with Resistant Hypertension

Corcept Therapeutics (NASDAQ: CORT) has launched the MOMENTUM clinical trial to investigate the prevalence of endogenous hypercortisolism (Cushing's syndrome) in patients with resistant hypertension.

PR Newswire
Mar 3rd, 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Corcept Therapeutics Incorporated - CORT

The investigation concerns whether Corcept and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

Insider Monkey
Feb 23rd, 2025
Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma Stock So Far in 2025

Corcept Therapeutics Incorporated (CORT): the Best Performing Pharma stock So Far in 2025.

Investing.com
Dec 30th, 2024
Corcept files NDA for new Cushing's syndrome drug

Corcept introduced Korlym(R), the first FDA-approved treatment for Cushing's syndrome, in February 2012.

INACTIVE